1,173 results on '"Gale, Richard"'
Search Results
2. An eye on equity: faricimab-driven health equity improvements in diabetic macular oedema using a distributional cost-effectiveness analysis from a UK societal perspective
3. The UK clinical eye research strategy: refreshing research priorities for clinical eye research in the UK
4. Baseline characteristics of eyes with early residual fluid post loading phase of aflibercept therapy in neovascular AMD: PRECISE study report 3
5. Cost-Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis
6. Associations of presenting visual acuity with morphological changes on OCT in neovascular age-related macular degeneration: PRECISE Study Report 2
7. Assessing the Art of Craft
8. Save our Sight (SOS): a collective call-to-action for enhanced retinal care across health systems in high income countries
9. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2
10. Optical coherence tomography imaging biomarkers associated with neovascular age-related macular degeneration: a systematic review
11. William James at the Boundaries: Philosophy, Science, and the Geography of Knowledge (review)
12. Improved Structure and Function in Early-Detected Second-Eye Neovascular Age-Related Macular Degeneration: FASBAT/Early Detection of Neovascular Age-Related Macular Degeneration Report 1
13. The MATE trial: a multicentre, mixed-methodology, pilot, randomised controlled trial in neovascular age-related macular degeneration
14. Assessing the structure of the posterior visual pathway in bilateral macular degeneration
15. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials
16. The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice
17. Current status and practical considerations of artificial intelligence use in screening and diagnosing retinal diseases: Vision Academy retinal expert consensus
18. The impact of artificial intelligence on retinal disease management: Vision Academy retinal expert consensus
19. Health technology assessment of new retinal treatments; the need to capture healthcare capacity issues
20. Subretinal transient hyporeflectivity in neovascular age-related macular degeneration and its response to a loading phase of aflibercept: PRECISE report 4
21. An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma
22. An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review
23. Improved structure and function in early detected second eye neovascular age-related macular degeneration; FASBAT/EDNA report 1
24. Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid
25. Predicting myocardial infarction through retinal scans and minimal personal information
26. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
27. Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysis.
28. Energy Medicine, the New Paradigm to Displace the Medical Establishment
29. Assessing functional reorganization in visual cortex with simulated retinal lesions
30. TENAYA and LUCERNE
31. Treatment of age‐related macular degeneration with aflibercept using a treat, extend and fixed protocol; A 4‐year study of treatment outcomes, durability, safety and quality of life (An extension to the MATE randomised controlled trial).
32. Baseline characteristics of eyes with early residual fluid post loading phase of aflibercept therapy in neovascular AMD: PRECISE study report 3
33. Associations of presenting visual acuity with morphological changes on OCT in neovascular age-related macular degeneration: PRECISE Study Report 2
34. How the Fingerprint Effect Applies to Digitized Fingerprint-Like Structures
35. Demographic and Clinical Factors that Influence the Visual Response to Anti-Vascular Endothelial Growth Factor Therapy in Patients with Neovascular Age-Related Macular Degeneration: A Systematic Review
36. Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration
37. Quantitative assessment of the outcome of anti-vascular endothelial growth factor treatment for neovascular macular degeneration
38. Wikipedia's Skeptical Assault on Botanical Medicine
39. Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group
40. Sink or SWMM: Simulating the Hydrological Effects of Retention Tanks in a Small Urban Catchment
41. Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept: The AQUA Study
42. Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study
43. Treatment of age‐related macular degeneration with aflibercept using a treat, extend and fixed protocol; A 4‐year study of treatment outcomes, durability, safety and quality of life (An extension to the MATE randomised controlled trial)
44. Correction: Save our Sight (SOS): a collective call-to-action for enhanced retinal care across health systems in high income countries
45. Corporal punishment: help for teachers
46. Quality of community care for the long-term mentally disabled
47. Conclusions
48. Stubborn Continuities
49. Introduction
50. Theorising ‘Race’, Ethnicity and Culture within Contemporary Planning
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.